← Back to Insights
October 25, 2023
Authors
David Burda
Topics
Economics Policy System Dynamics
Channels
Blogs

Putting a Price Tag on Healthcare Middlemen

Healthcare middlemen like group purchasing organizations, distributors and pharmacy benefit managers (PBMs) add costs to our already bloated healthcare system, not subtract costs through savings like they claim.

If you don’t believe me, read this short but telling research letter in JAMA Health Forum. Written by four researchers affiliated with the University of Utah and Johns Hopkins University, the research letter looks at the financial impact of spread pricing by PBMs. That’s when PBMs charge health insurers more than what the PBMs pay dispensing pharmacies for the same covered drugs. PBMs keep the difference.

The researchers’ study pool consisted of 45 generic drugs covered by Medicare Part D. For a drug to be included in the pool, more than two pharmaceutical manufacturers had to make the drug, the Medicare Part D program had to pay out more than $100 million each year for the drug, and more than a million Medicare beneficiaries had to use the drug.

In 2021, Medicare beneficiaries filed 690 million drug claims for those 45 drugs totaling $11.8 billion, per the study. The average cost per claim was $22.50.

The researchers broke down that average cost per claim by where the money went, and in 2021 it went as follows:

  • 40.8% went to the gross profit of PBMs.
  • 29.9% went to the revenue of drug manufacturers.
  • 17.2% went to the gross profit of dispensing pharmacies.
  • 12.0% went to the gross profit of drug wholesalers.

In short, only about 30% went to drug companies, and about 70% went to three intermediaries, or middlemen, between the drug maker and the drug user with most of that 70% share going to PBMs.

“Policy efforts prohibiting spread pricing practices of PBMs may lower claim-level revenue retained by PBMs for generic drugs,” the researchers said.

What do PBMs do to healthcare consumers again? Right. The same thing GPOs and distributors do to healthcare consumers.

Thanks for reading.

To learn more about this topic, please read:

About the Author

David Burda

David Burda began covering healthcare in 1983 and hasn’t stopped since. Dave writes this monthly column “Burda on Healthcare,” contributes weekly blog posts, manages our weekly newsletter 4sight Friday, and hosts our weekly Roundup podcast. Dave believes that healthcare is a business like any other business, and customers — patients — are king. If you do what’s right for patients, good business results will follow.

Dave’s personnel experiences with the healthcare system both as a patient and family caregiver have shaped his point of view. It’s also been shaped by covering the industry for 40 years as a reporter and editor. He worked at Modern Healthcare for 25 years, the last 11 as editor.

Prior to Modern Healthcare, he did stints at the American Medical Record Association (now AHIMA) and the American Hospital Association. After Modern Healthcare, he wrote a monthly column for Twin Cities Business explaining healthcare trends to a business audience, and he developed and executed content marketing plans for leading healthcare corporations as the editorial director for healthcare strategies at MSP Communications.

When he’s not reading and writing about healthcare, Dave spends his time riding the trails of DuPage County, IL, on his bike, tending his vegetable garden and daydreaming about being a lobster fisherman in Maine. He lives in Wheaton, IL, with his lovely wife of 40 years and his three children, none of whom want to be journalists or lobster fishermen.

Recent Posts

Economics
AMA Draws Blood With Policy on Hospital Tax Exemptions
There are certain lines you don’t cross, even when you point the finger at another healthcare industry sector… Read More
By November 20, 2024
System Dynamics
Burda on Healthcare: It’s Open Season on Employer Benefits Surveys
It’s that time of year when people choose their health insurance benefits and select a health plan. Not… Read More
By November 12, 2024
Economics
It’s Big Pharma’s Turn to Point the Finger
It’s time for another installment of my healthcare blame game series. The series is based on my theory… Read More
By November 6, 2024